li song

Dr. li song

Henan University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
CXChenyang Xu
Chenyang Xu
BYBingjian Yuan
Bingjian Yuan
THTao He
Tao He
BDBingqian Ding
Bingqian Ding
LSli song
li song
M6A methylation is likely to be closely associated with the occurrence and development of tumours. In this study, we demonstrated that the transcription levels of the m6A RNA methylation regulators are closely related to the prognosis of glioma. Univariate Cox analysis was performed on the expression levels of methylation regulators and selected three hub genes in glioma. Next, we systematically compared the expression of these m6A RNA methylation regulators in gliomas with different clinicopathological features. The overall survival (OS) curve of the hub genes was initially established based on TCGA database information. YTHDF1 was selected from the hub genes following survival and prognosis analysis. A nomogram was developed to predict the survival probability. We further performed cell function and in vivo xenograft tumour experiments to further verify its role in tumour progression. Next, based on the miRanda and miRDB databases, we predicted one microRNA, hsa‐mir‐346, that might regulate and bind to 3'UTR of YTHDF1, which was confirmed by our fluorescent enzyme reporter gene experiment. In summary, m6A RNA methylation regulators play a potential role in the progression of gliomas. YTHDF1 may have an essential function in glioma diagnosis, treatment and prognosis.

14 December 2015 in Herz
Verified
Journal Article
Closed access
PDF file
YZYunyue Zhao
Yunyue Zhao
LPL. Peng
L. Peng
YLYe Luo
Ye Luo
LSli song
li song
ZZZ. Zheng
Z. Zheng
JLJ. Liu
J. Liu


5 July 2024 in Medicine
Verified
Journal Article
Open access
LSli song
li song
RLRuoxuan Liu
Ruoxuan Liu
XHXuexue Hao
Xuexue Hao
XLXiaoqiang Liu
Xiaoqiang Liu
The potential relationship between the gut microbiota and prostate cancer, possibly influenced by immune cells, remains unclear. This study employed the mediation Mendelian randomization (MR) technique to investigate the causal link between the gut microbiota, immune cells, and prostate cancer. Data on immune cell activity were sourced from Valeria Orrù’s research, whereas the genome-wide association study outcome dataset was obtained from the Integrative Epidemiology Unit database. The bidirectional MR analysis utilized 5 different methods: inverse variance weighted (IVW), weighted median, MR-Egger regression, weighted mode, and simple mode. In addition, the mediating effect of immune cells on the gut microbiota and prostate cancer was explored using mediation analysis. Eighty-three single nucleotide polymorphisms associated with prostate cancer were screened as instrumental variables. In a positive MR analysis with gut microbiota as the exposure factor, IVW showed an association between 8 gut microbiota and prostate cancer. Additionally, 9 types of immune cells have been found to be associated with prostate cancer using methods such as IVW. MR analysis of the gut microbiota on immune cells (beta1) revealed a negative correlation between Bifidobacterium and CD39 + T regulatory cells (Tregs; odds ratio [OR] = 0.785, 95% confidence interval [CI] = 0.627–0.983, P = .03). Furthermore, MR analysis of immune cells in prostate cancer disease (beta2) showed that CD39 + Tregs are a risk factor for prostate cancer (OR = 1.215, 95% CI = 1.027–1.354, P = .04). Moreover, MR analysis of gut microbiota in prostate cancer (total effect) indicated that Bifidobacterium is a protective factor for prostate cancer (OR = 0.905, 95% CI = 0.822–0.977, P = .04). The sensitivity analysis verified the robustness of the above results. Mediation analysis demonstrated that CD39 + Tregs partially mediate the causal relationship between Bifidobacterium and prostate cancer. This study demonstrates that Bifidobacterium inhibits prostate cancer progression through CD39 + Tregs as mediators, providing new ideas and approaches for the treatment and prevention of prostate cancer.

1 October 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JZJianhua Zhang
Jianhua Zhang
RLRuoxuan Liu
Ruoxuan Liu
XWXue Wang
Xue Wang
LZLeiguang Zhang
Leiguang Zhang
WPWeidong Pei
Weidong Pei
LSli song
li song
The escalating global burden of opioid use disorder (OUD) necessitates a nuanced understanding of its epidemiological patterns, socioeconomic determinants, and temporal trends. This study quantifies the global, regional, and national burden of OUD-related mortality and disability, evaluates policy correlates, and identifies critical disparities across demographic and socioeconomic strata. Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017–2021, we analyzed age-standardized mortality rates (ASMRs), disability-adjusted life years (DALYs), and their 95% uncertainty intervals (UIs) across 204 countries and territories. Joinpoint regression modeled temporal trends, while multivariable generalized estimating equations (GEEs) assessed socioeconomic gradients via the Socio-demographic Index (SDI). Geospatial clustering was evaluated using Moran’s I statistic. Robustness was confirmed through sensitivity analyses, counterfactual modeling, and cross-validation. Globally, OUD mortality increased by 12.4% between 2017 and 2021, with the Americas remaining the epicenter (ASMR: 5.72 per 100,000; +47.3% deaths). Europe demonstrated progress (mortality decline: -1.8%), while Asia and Africa faced rising chronic disability (DALYs: +3.0% and + 10.2%, respectively). National-level extremes ranged from 0.01 per 100,000 in Japan to 7.16 per 100,000 in Canada. A pronounced socioeconomic gradient emerged: high-SDI regions exhibited 17.8-fold higher mortality rates (0.641% vs. 0.036% in low-SDI regions) and 13.9-fold greater DALY rates. Sex disparities persisted (male-to-female mortality ratio: 4.7:1), with males experiencing biphasic trends (+ 3.8% annual percent change [APC] pre-2020, -6.5% post-2020). Geospatial analyses revealed diverging trajectories, including rising mortality in the Americas (+ 4.2% APC) and declines in Africa (-3.1% APC). This study highlights stark regional and socioeconomic disparities in the OUD burden, exacerbated by synthetic opioid proliferation in high-income settings and chronic disability in resource-limited regions. Evidence-based harm reduction policies in high-SDI nations mitigated disability, while low-SDI regions faced accelerating crises. Targeted interventions addressing socioeconomic inequities, gender-specific risks, and geospatial vulnerabilities are urgently needed to curb the global opioid epidemic.

21 August 2020 in Aging
Verified
Journal Article
Closed access
KYKunhou Yao
Kunhou Yao
LWLunshou Wei
Lunshou Wei
JZJunjie Zhang
Junjie Zhang
CWChenyu Wang
Chenyu Wang
CWChaoyang Wang
Chaoyang Wang
LSli song
li song
The survival rate of stomach adenocarcinoma patients with immune and stromal scores and different clinicopathological features obtained from the TCGA datasets was systematically compared. A list of genes that are correlated with stomach adenocarcinoma microenvironment were extracted using the TCGA database to predict the prognosis and survival. In addition, the differentially expressed genes were extracted by comparing the immune and stromal scores of the groups. The protein-protein interaction network, and functional and pathway enrichment analyses of differentially expressed genes were performed. A total of 8 hub genes were selected from the differentially expressed genes to predict the overall survival and disease-free survival rates. GPNMB was selected from the hub genes based on the survival and prognosis analyses. A nomogram was built by including the potential risk factors based on multivariate Cox analysis. Cell function experiments and xenograft tumors were conducted in vivo to further verify the role of GPNMB in tumor progression. The predicted microRNA, miR-30b-3p, might act as upstream negative regulator and binding to 3' UTR of GPNMB, confirming by fluorescent enzyme reporter gene experiment. In summary, immune-related scores are crucial factors in the malignant progression of stomach adenocarcinoma and GPNMB acts as a potentially useful prognostic factor for stratification and in developing the treatment strategy